Key result
Inhibiting ZEB2 SUMOylation protects against adverse post-MI remodeling by upregulating Nr4a1.
Why the study?
The role and post-translational regulation of ZEB2 in cardiac fibroblast-to-myofibroblast transition and fibrosis following myocardial infarction are not fully understood.
Does genetic ablation of ZEB2 SUMOylation prevent adverse cardiac remodeling and dysfunction post-myocardial infarction in preclinical models?
Does genetic ablation of ZEB2 SUMOylation prevent adverse cardiac remodeling and dysfunction post-myocardial infarction in preclinical models?
SUMO-1 modification of ZEB2 drives pathological cardiac remodeling after myocardial infarction, and its inhibition protects against cardiac dysfunction and fibrosis by relieving repression of Nr4a1.
Hypothesis-generating for ZEB2 SUMOylation inhibition post-MI; leaves open translation to human cardioprotection.
The transcription factor ZEB2 has been implicated in cardiovascular disease, but its role and post-translational regulation in cardiac fibroblast-to-myofibroblast transition (FMT) and fibrosis after myocardial infarction (MI) are not fully understood. ZEB2 protein expression was significantly increased in infarcted murine hearts, activated cardiac fibroblasts, and human fibrotic myocardium. Myofibroblast-specific ZEB2 knockout alleviates cardiac dysfunction and adverse remodeling post-MI. Mechanistically, SENP1 regulated SUMO-1 modification of ZEB2 at K462, K479, K611, and K774. Reconstituting ZEB2-deficient systems with wild-type ZEB2 (ZEB2-WT) restored pathological fibrosis and FMT, whereas the SUMOylation-deficient mutant (ZEB2-4KR) conferred cardioprotective effects. ZEB2 SUMOylation activated the pro-fibrotic PI3K/AKT-mTORC1 signaling pathway. ZEB2-4KR weakens CtBP1 binding and enhances ZEB2 occupancy at the Nr4a1 promoter. Importantly, Nr4a1 knockdown abolished the protective effects of ZEB2-4KR. These findings identify SUMO-1 modification of ZEB2 as a central driver and molecular switch of pathological cardiac remodeling after MI and suggest that targeting ZEB2 SUMOylation may represent a promising therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Myocardial infarction and cardiac remodeling. ZEB2 SUMOylation deficiency (ZEB2-4KR mutant) vs. ZEB2-WT or GFP control was evaluated on Cardiac dysfunction and adverse remodeling post-MI (ejection fraction, fractional shortening, infarct size).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: